Genomics Likely to Replace Traditional Drug Therapies in Treating CHF

NEW YORK, April 17 /PRNewswire/ -- The market for congestive heart failure
(CHF) drug treatments was estimated at $18 billion in 2007, and is expected to
reach $30 billion by 2017, according to a new report by Kalorama Information,
Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical
Management. Growth is being driven by three factors: an increased incidence of
CHF, the application of innovative technologies in search of targeted
therapies which is creating opportunity for new entrants into this market, and
physicians prescribing multi-drug regimens in response to the failure of
traditional drugs to treat CHF.
CHF is a complex disorder for which prevention is more effective than
treatment, and as part of the larger cardiovascular markets, it is mostly
treated with drugs used to treat many other cardiovascular disorders. The lack
of targeted treatments means drugs will continue to be applied liberally for
prevention and sales will grow disproportionately to the CHF patient
population.
"The future of CHF drug treatments lies in newer technologies such as
biotechnology and genomics," notes Kenneth Krul, the report's analyst. "The
identification of fetal genes associated with CHF, new treatments that address
the endothelium and cell therapy to regenerate damaged heart muscle tissue
present some promising areas."
The market for drugs to treat CHF will continue to be dominated by major
pharmaceutical companies which supply product lines with broad cardiovascular
applications. There are, however, many smaller companies focusing primarily on
CHF and biotech, and their numbers are growing with the realization that this
disease presents a major economic opportunity for which there is currently no
adequate answer.
Kalorama Information's report Congestive Heart Failure: Major World
Markets, Volume I: Pharmaceutical Management focuses on the market potential
resulting from the application of current and advanced pharmaceutical and
biopharmaceutical technology to the development of CHF treatments in the U.S.,
France, Germany, Italy, Spain, United Kingdom and Japan, providing forecasts
through 2017. The report can be purchased directly from Kalorama Information
by visiting
http://www.kaloramainformation.com/Congestive-Heart-Failure-1399514/.
About Kalorama Information
Kalorama Information supplies the latest in independent market research in
the life sciences, as well as a full range of custom research services.
Kalorama routinely assists media with healthcare topics, and can provide
experts to speak about markets in the life sciences industry. For more
information, contact Andrea Hiller at 212-807-2673 or
press@kaloramainformation.com, or visit http://www.kaloramaInformation.com.
SOURCE Kalorama Information

Andrea Hiller of Kalorama Information, +1-212-807-2673,
press@kaloramainformation.com